In a recent study it was found that Modified Citrus Pectin (MCP) can boost the anti-cancer effects of two poly-botanical formula.
It was found that when co-administered with formulas that attack breast and prostate cancer, MCP significantly increased their anti-cancer action, further cutting down the metastasis in highly invasive breast and prostate cancer cells.
The study was led by researchers at the Cancer Research Laboratory at Indiana University Health and Indiana University School of Medicine.
"We asked a simple question of whether one plus one can equal more than two," said lead investigator Dr. Daniel Sliva, associate professor at the Indiana University School of Medicine.
"We know that certain molecules in cancer cells are responsible for their aggressive behavior. The synergistic effects seen in this study show that we can further suppress these molecules and significantly reduce the cancer cells' aggressiveness," said Sliva.
In the study, low concentrations of the anti-breast cancer formula reduced breast cancer cell adhesion to human fibronectin by 21 percent.
However, when co-administered with Modified Citrus Pectin, researchers observed a 40 percent decrease in the malignant cells.
In addition, the anti-prostate cancer formula, when administered alone, reduced prostate cancer cell adhesion by 9 percent.
And when MCP was added, adhesion was suppressed by up to 40 percent.
The study also showed that cancer cell migration was also decreased by combining MCP with the prostate and breast formulas.
"This new study is particularly important because it demonstrates that when MCP is combined with either the prostate or breast formula, lower dosages provided more powerful synergistic anti-cancer effects than were observed when these supplements were studied on their own," added Dr. Isaac Eliaz, co-author and formulator.
This study has been published in the peer review journal Integrative Cancer Therapies.